Insider Selling: uniQure (NASDAQ:QURE) CEO Sells 28,716 Shares of Stock

Posted by Geri Gentry on Jun 26th, 2026

uniQure N.V. (NASDAQ:QURE – Get Free Report) CEO Matthew Kapusta sold 28,716 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $50.02, for a total transaction of $1,436,374.32. Following the sale, the chief executive officer directly owned 519,227 shares in the company, valued at $25,971,734.54. This trade represents a 5.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Stock Performance

Shares of NASDAQ:QURE traded down $1.59 during trading on Friday, hitting $47.51. 3,154,443 shares of the company traded hands, compared to its average volume of 2,765,936. The stock has a market capitalization of $3.00 billion, a price-to-earnings ratio of -13.65 and a beta of 0.98. The business’s fifty day moving average is $27.23 and its 200-day moving average is $22.85. uniQure N.V. has a one year low of $8.73 and a one year high of $71.50. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. As a group, equities analysts predict that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets

QURE has been the topic of a number of research reports. Sanford C. Bernstein downgraded uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. Mizuho raised their target price on uniQure from $35.00 to $68.00 and gave the company an “outperform” rating in a research note on Thursday. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Stifel Nicolaus set a $28.00 price target on shares of uniQure in a report on Tuesday, May 5th. Finally, Barclays raised shares of uniQure from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $25.00 to $65.00 in a report on Thursday, June 18th. Twelve analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and an average target price of $61.67.

View Our Latest Analysis on QURE

Institutional Investors Weigh In On uniQure

Large investors have recently modified their holdings of the stock. Woodline Partners LP raised its position in shares of uniQure by 25.0% during the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after purchasing an additional 35,175 shares during the period. Legal & General Group Plc acquired a new position in shares of uniQure in the 2nd quarter valued at $497,000. Marshall Wace LLP increased its stake in uniQure by 276.5% in the 2nd quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock worth $3,108,000 after purchasing an additional 163,749 shares in the last quarter. California State Teachers Retirement System purchased a new position in uniQure in the 2nd quarter worth about $540,000. Finally, Ameriprise Financial Inc. raised its holdings in uniQure by 38.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock worth $10,622,000 after buying an additional 212,218 shares during the period. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

(Get Free Report)

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.